The World Health Organization (WHO) today announced recommendations for the viral composition of influenza vaccines for the 2025 influenza season in the Southern Hemisphere. The announcement was made during a briefing after a four-day conference on the composition of influenza virus vaccines. The conference is held twice a year, once in the Southern Hemisphere and once in the Northern Hemisphere.
WHO organized this consultation with an advisory group of experts drawn from WHO Collaborating Centers and WHO Essential Regulation Laboratories to analyze influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). Masu. The published recommendations will be used by national vaccine regulators and pharmaceutical companies to develop, produce and license influenza vaccines for the next influenza season.
Due to the circulating and constantly evolving nature of influenza viruses, including those that infect humans, the viruses in influenza vaccines require regular updates for the vaccine to be effective.
WHO recommends that trivalent vaccines for the 2025 Southern Hemisphere influenza season include:
egg-based vaccines
A/Victoria/4897/2022 (H1N1)pdm09-like virus, A/Croatia/10136RV/2023 (H3N2)-like virus. Viruses like anda B/Austria/1359417/2021 (B/Victoria strain).
Cell culture vaccines, recombinant protein vaccines, or nucleic acid-based vaccines
A/Wisconsin/67/2022 (H1N1)pdm09-like virus, A/District of Columbia/27/2023 (H3N2)-like virus. Viruses like anda B/Austria/1359417/2021 (B/Victoria strain).
Recommendations for the B/Yamagata lineage component of quadrivalent influenza vaccines remain unchanged from previous recommendations.
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Source link
